Back to top
more

Alnylam Pharmaceuticals (ALNY)

(Delayed Data from NSDQ)

$147.76 USD

147.76
506,806

-1.62 (-1.08%)

Updated May 24, 2024 04:00 PM ET

After-Market: $147.87 +0.11 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is Nuveen ESG MidCap Growth ETF (NUMG) a Strong ETF Right Now?

Smart Beta ETF report for NUMG

Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22

Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

VERA Dips Despite Positive Data From IgA Nephropathy Study

VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.

Clovis (CLVS) Down 18.1% Since Last Earnings Report: Can It Rebound?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy

Alnylam (ALNY) initiates label expansion filing with FDA for Onpattro to treat cardiomyopathy in patients suffering from ATTR-amyloidosis. The drug is already approved to treat polyneuropathy in such patients.

Why Is Intercept (ICPT) Down 3.9% Since Last Earnings Report?

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3

Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.

Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of -78.49% and 7.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks' Q3 Earnings on Oct 27: MRK, GILD & More

Let's analyze how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Oct 27.

Analysts Estimate Harmony Biosciences Holdings, Inc. (HRMY) to Report a Decline in Earnings: What to Look Out for

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q3 Earnings Expected to Decline

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alnylam (ALNY) Soars 3.6%: Is Further Upside Left in the Stock?

Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion

The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.

Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod

The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study

Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.

Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?

Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why

Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q2

Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.

Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Misses Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of -41.36% and 13.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stocks' Q2 Earnings on Jul 28: MRK, PFE & More

Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Jul 28.